Publisher Correction: Radioactive drugs emerge from the shadows to storm the market.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30659240.
- Also identified by DOI 10.1038/s41587-019-0030-5.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the version of this article initially published, Betalutin was described as directing a radioisotope to CD45-expressing B cells; in fact, it directs it to CD37-expressing B cells. The error has been corrected in the HTML and PDF versions of the article.